Tenax Therapeutics, Inc. (TENX) stock is up by 26% as of 11:20 a.m. EDT, in this morning. The company released the positive data from the company’s Phase 2 HELP Study today, and this trial results was already published in the Journal of American College of Cardiology: Heart Failure.
The HELP (Hemodynamic Evaluation of Levosimendan in heart failure with preserved ejection fraction) Study was designed as a randomized placebo-controlled trial to evaluate the hemodynamic and clinical effects of weekly levosimendan IV infusions in heart failure with preserved ejection fraction patients.
Results reported in the publication include an responder rate of 84% during the open-label phase as 37 of 44 patients met responder criteria. The authors concluded that levosimendan is the first drug to demonstrate improved cardiovascular hemodynamics and a statistically significant increase in six-minute walk distance seen compared to placebo.
The company said that 84% of the patients enrolled in the initial lead-in phase had a significant hemodynamic response at rest and with exercise during cardiac catheterization provides confidence that levosimendan may be an important treatment for these patients who have a large unmet need.
Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.